Cargando…

Retraction: The role of Janus kinase/STAT3 pathway in hematologic malignancies with an emphasis on epigenetics

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507460/ https://www.ncbi.nlm.nih.gov/pubmed/37732321 http://dx.doi.org/10.3389/fgene.2023.1285098

Ejemplares similares

The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics
por: Zeinalzadeh, Elham, et al.
Publicado: (2021)

Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases
por: Liu, Man, et al.
Publicado: (2018)

Role of IL-9 and STATs in hematological malignancies (Review)
por: CHEN, NA, et al.
Publicado: (2014)

Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer
por: Berishaj, Marjan, et al.
Publicado: (2007)

Epigenetics of hematopoiesis and hematological malignancies
por: Hu, Deqing, et al.
Publicado: (2016)

Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies
por: Rodriguez Moncivais, Omar J., et al.
Publicado: (2023)

The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies
por: Leśniak, Maria, et al.
Publicado: (2023)

Targeted Epigenetic Interventions in Cancer with an Emphasis on Pediatric Malignancies
por: Gaál, Zsuzsanna
Publicado: (2022)

Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies
por: Castillo, Jorge J, et al.
Publicado: (2014)

The Beginning of the Road for Non-Coding RNAs in Normal Hematopoiesis and Hematologic Malignancies
por: Heuston, Elisabeth F., et al.
Publicado: (2011)

Long non-coding RNAs in hematologic malignancies: road to translational research
por: Hajjari, Mohammadreza, et al.
Publicado: (2013)

Implication of microRNAs in Carcinogenesis with Emphasis on Hematological Malignancies and Clinical Translation
por: Gaál, Zsuzsanna
Publicado: (2022)

NFE2L3 as a Novel Biomarker Associated With IL-2/STAT5/NLRP3 Signaling Pathway in Malignant Pleural Mesothelioma and Other Cancers
por: Wang, Zhen, et al.
Publicado: (2022)

Janus Kinase 3 phosphorylation and the JAK/STAT pathway are positively modulated by follicle-stimulating hormone (FSH) in bovine granulosa cells
por: Zareifard, Amir, et al.
Publicado: (2023)

The Interaction Between Autophagy and JAK/STAT3 Signaling Pathway in Tumors
por: Xu, Jiangyan, et al.
Publicado: (2022)

The two faces of Janus kinases and their respective STATs in mammary gland development and cancer
por: Wagner, Kay-Uwe, et al.
Publicado: (2011)

The Epigenetic Cytocrin Pathway to the Nucleus. Epigenetic Factors, Epigenetic Mediators, and Epigenetic Traits. A Biochemist Perspective
por: Navarro, Gemma, et al.
Publicado: (2017)

The role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignancies
por: Yamada, Osamu, et al.
Publicado: (2013)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies
por: Arora, Loukik, et al.
Publicado: (2018)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease
por: Zeng, Zhen, et al.
Publicado: (2019)

Interferon-γ Suppresses Intestinal Epithelial Aquaporin-1 Expression via Janus Kinase and STAT3 Activation
por: Dicay, Michael S., et al.
Publicado: (2015)

Protective Effect of Alprostadil on Acute Pancreatitis in Rats via Inhibiting Janus Kinase 2 (JAK2)/STAT3 Signal Transduction Pathway
por: Fei, Shuke, et al.
Publicado: (2019)

Role of Wnt canonical pathway in hematological malignancies
por: GE, Xueling, et al.
Publicado: (2010)

Polymorphism of alpha-1-antitrypsin in hematological malignancies
por: Topic, Aleksandra, et al.
Publicado: (2009)

News and Views on STAT3 Psychopathology
por: Sadok, Sara H., et al.
Publicado: (2021)

SBNO2 is a critical mediator of STAT3-driven hematological malignancies
por: Brandstoetter, Tania, et al.
Publicado: (2023)

Takinib Inhibits Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts by Targeting the Janus Kinase-Signal Transducer and Activator of Transcription 3 (JAK/STAT3) Pathway
por: Panipinto, Paul M., et al.
Publicado: (2021)

Role of janus kinase inhibitors in the treatment of alopecia areata
por: Triyangkulsri, Korn, et al.
Publicado: (2018)

Targeting the JAK2/STAT3 Pathway—Can We Compare It to the Two Faces of the God Janus?
por: Jaśkiewicz, Anna, et al.
Publicado: (2020)

Epigenetic inactivation of the MIR129-2 in hematological malignancies
por: Wong, Kwan-Yeung, et al.
Publicado: (2013)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications
por: Solayappan, Maheswaran, et al.
Publicado: (2022)

Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
por: Samaka, Rehab M, et al.
Publicado: (2019)

Interferon-γ induces interleukin-6 production by neutrophils via the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway
por: Yoshida, Shuhei, et al.
Publicado: (2021)

Versican G1 domain enhances adenoviral-mediated transgene expression and can be modulated by inhibitors of the Janus kinase (JAK)/STAT and Src family kinase pathways
por: Akinfenwa, Patricia Y., et al.
Publicado: (2017)

Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition
por: Zhu, Hua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0kt7cno1nj5kc50225ckeu9ng2